BIOCARDIA INC (BCDA) Fundamental Analysis & Valuation

NASDAQ:BCDA • US09060U6064

Current stock price

1.2 USD
+0.04 (+3.45%)
At close:
1.1903 USD
-0.01 (-0.81%)
After Hours:

This BCDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BCDA Profitability Analysis

1.1 Basic Checks

  • BCDA had negative earnings in the past year.
  • BCDA had a negative operating cash flow in the past year.
  • BCDA had negative earnings in each of the past 5 years.
  • BCDA had a negative operating cash flow in each of the past 5 years.
BCDA Yearly Net Income VS EBIT VS OCF VS FCFBCDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -421.11%, BCDA is doing worse than 93.42% of the companies in the same industry.
Industry RankSector Rank
ROA -421.11%
ROE N/A
ROIC N/A
ROA(3y)-240.8%
ROA(5y)-173.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCDA Yearly ROA, ROE, ROICBCDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • BCDA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCDA Yearly Profit, Operating, Gross MarginsBCDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. BCDA Health Analysis

2.1 Basic Checks

  • BCDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for BCDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCDA Yearly Shares OutstandingBCDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
BCDA Yearly Total Debt VS Total AssetsBCDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -123.97, we must say that BCDA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -123.97, BCDA is doing worse than 94.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -123.97
ROIC/WACCN/A
WACC9.19%
BCDA Yearly LT Debt VS Equity VS FCFBCDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 0.33 indicates that BCDA may have some problems paying its short term obligations.
  • The Current ratio of BCDA (0.33) is worse than 92.26% of its industry peers.
  • BCDA has a Quick Ratio of 0.33. This is a bad value and indicates that BCDA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.33, BCDA is doing worse than 91.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
BCDA Yearly Current Assets VS Current LiabilitesBCDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BCDA Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 19.34% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.16%
EPS Next 2Y16.77%
EPS Next 3Y19.34%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCDA Yearly Revenue VS EstimatesBCDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2028 2M 4M 6M 8M
BCDA Yearly EPS VS EstimatesBCDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. BCDA Valuation Analysis

4.1 Price/Earnings Ratio

  • BCDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BCDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCDA Price Earnings VS Forward Price EarningsBCDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCDA Per share dataBCDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • BCDA's earnings are expected to grow with 19.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.77%
EPS Next 3Y19.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCDA Dividend Analysis

5.1 Amount

  • No dividends for BCDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BCDA Fundamentals: All Metrics, Ratios and Statistics

BIOCARDIA INC

NASDAQ:BCDA (4/2/2026, 8:09:21 PM)

After market: 1.1903 -0.01 (-0.81%)

1.2

+0.04 (+3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24
Earnings (Next)05-12
Inst Owners6.12%
Inst Owner Change52.09%
Ins Owners18.47%
Ins Owner Change5.28%
Market Cap12.73M
Revenue(TTM)N/A
Net Income(TTM)-8.80M
Analysts82.5
Price Target25.5 (2025%)
Short Float %2.47%
Short Ratio2.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.37%
Min EPS beat(2)-48.32%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)20.95%
Min EPS beat(4)-48.32%
Max EPS beat(4)60.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)61.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS-0.18
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -421.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-240.8%
ROA(5y)-173.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.91%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z -123.97
F-Score2
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)36.91%
Cap/Depr(5y)70.72%
Cap/Sales(3y)6.02%
Cap/Sales(5y)9.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y35.16%
EPS Next 2Y16.77%
EPS Next 3Y19.34%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.9%
EBIT Next 3Y-11.84%
EBIT Next 5Y-0.64%
FCF growth 1Y21.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.07%
OCF growth 3YN/A
OCF growth 5YN/A

BIOCARDIA INC / BCDA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOCARDIA INC?

ChartMill assigns a fundamental rating of 0 / 10 to BCDA.


Can you provide the valuation status for BIOCARDIA INC?

ChartMill assigns a valuation rating of 0 / 10 to BIOCARDIA INC (BCDA). This can be considered as Overvalued.


What is the profitability of BCDA stock?

BIOCARDIA INC (BCDA) has a profitability rating of 0 / 10.


How financially healthy is BIOCARDIA INC?

The financial health rating of BIOCARDIA INC (BCDA) is 0 / 10.